KMT2A and leukemia: A second independently executed study was designed to specifically address the urgent need for novel therapeutics for KMT2A-r leukemias and entailed a high-throughput screen for drugs that specifically deplete oncogenic MLL fusion proteins, using a reporter cell line for MLL fusion protein expression [8].